CTChris Twelves

Chris Twelves

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chris Twelves has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 5-Fluorouracil (5FU) intratumoural pharmacokinetics: Rapid uptake in cells and in spheroids (SPH)

    by M. Jove, P. Loadman, J. Wicks, J. Spencer, A. Race, R. Salazar, C.J. Twelves

    Background: Limited data are available on 5FU intratumoral pharmacokinetics. Previous studies with radiolabeled 5FU showed homogeneous uptake in spheroids within a few minutes (Cancer Chemother Pharmacol. 1984;13(2):131-5) but no quantification was done. We present data on intracellular and intra-spheroidal 5FU uptake; drug efflux experiments are on-going and results will be presented.

  • Lebensqualität von Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs nach Vorbehandlung mit Anthrazyklinen und Taxanen unter der Behandlung mit Eribulin oder Capecitabin: eine randomisierte, unverblindete Phase III-Studie

    by J Cortes, A Awada, Pa Kaufman, L Yelle, Ea Perez, G Velikova, J Wanders, M Olivo, Y He, C Dutcus, et al.

    Poster Retreat vom ASCO 2013. Zielsetzung: Eine Phase III-Studie zum Vergleich Eribulin (E) gegen Capecitabin (C) bei Patientinnen mit lokal fortgeschrittenem oder metastasiertem Brustkrebs (mBC) konnte keine statistisch signifikante Überlegenheit hinsichtlich PFS oder OS zeigen. Die Verträglichkeitsprofile entsprachen bekannten Nebenwirkungen. Hier werden die Lebensqualitätsdaten (QoL) vorgestellt. Materialien und Methoden: Patientinnen erhielten entweder 1,23 mg E/m2 an Tag 1 und 8 oder C 1,25 g/m2 2x täglich p.o. an Tag 1 – 14 in einem 21 Tage Zyklus. Patientinnen mussten vorherige Behandlung mit Anthrazyklin oder Taxan erhalten haben und erhielten die Studienmedikamente als Erst-, Zweit-, oder Drittlinientherapie für fortgeschrittene Erkrankung. Lebensqualität wurde als sekundärer Endpunkt mittels EORTC QLQ-C30 und QLQ-BR23 Fragebögen bei Studienbeginn, nach 6 Wochen, 3, 6, 12, 18 und 24 Monaten nach Behandlungsbeginn (oder bis Progression/Therapiewechsel) sowie bei ungeplanten Studienvisiten bestimmt. Longitudinale Analysen wurden anhand von gewichteten allgemeinen Schätzfunktionen durchgeführt, wobei für nicht-zufällige Abgänge durch Lebensverlust innerhalb von 12 Monaten adjustiert wurde. Covariate Faktoren waren die Zeit (Studienvisite), Region und Lebensqualität bei Studienbeginn. Primärer Endpunkt: Veränderung versus Baseline des Global Health Status (GHS/QoL insgesamt); explorativ: Änderung versus Studienbeginn für einzelne Funktionsbereiche und Parameter/Symptome. Ergebnisse: 1102 randomisierte Patientinnen (E 554; C 548) mit niedrigen GHS/QoL Scores (E 56,3; C 54,7 [100 = beste QoL zeigten unter E signifikant stärkere Besserung von GSH/QoL und kognitiver Funktion (E vs. C 6,5 [p = 0,048] bzw. 15,3 [p < 0,001]. C zeigte für emotionale Funktionalität signifikant stärkere Besserung (C vs. E 3,3 [p = 0,033]). Die Stärke von Schmerzen zu Studienbeginn und Abnahme unter Therapie war vergleichbar für E und C. Patienten berichteten unter E von weniger Anzeichen/Symptomen wie Übelkeit und Erbrechen (-1,9; p = 0,043) und Diarrhö (-3,7; p = 0,001). Unter C wurden weniger systemische unerwünschte Wirkungen (5,2; p < 0,001) und Probleme mit Haarverlust berichtet (9,3; p = 0,023). Zusammenfassung: GHS/QoL Scores verbesserten sich stärker bei Patienten unter E als C. Eribulin zeigte Vorteile hinsichtlich gastrointestinaler Effekte, C zeigte Vorteile hinsichtlich Haarverlust.

  • Open Access

    Poster session 6. Phase 1 studies

    by D. Pollyea, L. Gore, J. Gutman, S. G. Eckhardt, N. Hagelstrom, S. Coutre, M. Thirman, J. Byrd, G. Massimini, B. Laffranchi, et al.

  • 5006 ORAL Eribulin Mesylate EMBRACE Study – Survival Analysis Excluding Patients Re-challenged With Therapies of the Same Class

    by F. Cardoso, C. Twelves, L.T. Vahdat, C. Dutcus, S. Seegobin, J. Wanders, J. Cortes, J. O'Shaughnessy


  • Open Access

    A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer

    by C. Twelves, S. Gollins, R. Grieve, L. Samuel

    Background: Traditionally, metastatic colorectal cancer (MCRC) has been treated with intravenous (i.v.) 5-fluorouracil/leucovorin (5-FU/LV). The tumour-activated, oral fluoropyrimidine capecitabine demonstrates superior activity and favourable safety compared with the Mayo regimen, while potentially avoiding the complications and inconvenience associated with i.v. regimens. Patients and methods: Ninety-seven patients with previously untreated advanced/MCRC were randomised to receive capecitabine followed by i.v. 5-FU/LV [Mayo Clinic, in-patient de Gramont (IPdG) or out-patient modified de Gramont (OPdG) regimens], or i.v. 5-FU/LV followed by capecitabine. Results: Before treatment, of those patients for whom a preference was recorded, almost all (95%) preferred oral treatment (consistent across all treatment groups) and the majority retained this preference after treatment (64% overall; 86%, 63% and 50% in the Mayo, IPdG and OPdG groups, respectively). Following treatment, the principal reasons for oral treatment preference were increased convenience, home-based administration and tablet formulation. Treatment satisfaction was significantly higher with capecitabine compared with Mayo (P P P Conclusions: This study confirmed that the majority of patients with MCRC prefer oral to i.v. therapy, although the OPdG regimen appears to be the most popular i.v. option. Capecitabine clearly represents an effective, well-tolerated oral alternative to i.v. 5-FU/LV.


  • Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study

    by Chris J. Twelves, Charles A. Butts, Jim Cassidy, Thierry Conroy, Filippo de Braud, Eduardo Díaz-Rubio, Josep M. Tabernero, Patrick Schöffski, Arie Figer, René Brunet, et al.


  • Top Cited Papers
    Open Access

    Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    by Chris Twelves, Alfred Wong, Marek P. Nowacki, Markus Abt, Howard Iii Burris, Alfredo Carrato, Jim Cassidy, Andrés Cervantes, Jan Fagerberg, Vassilis Georgoulias, et al.

    Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting. We randomly assigned a total of 1987 patients with resected stage III colon cancer to receive either oral capecitabine (1004 patients) or bolus fluorouracil plus leucovorin (Mayo Clinic regimen; 983 patients) over a period of 24 weeks. The primary efficacy end point was at least equivalence in disease-free survival; the primary safety end point was the incidence of grade 3 or 4 toxic effects due to fluoropyrimidines. Disease-free survival in the capecitabine group was at least equivalent to that in the fluorouracil-plus-leucovorin group (in the intention-to-treat analysis, P<0.001 for the comparison of the upper limit of the hazard ratio with the noninferiority margin of 1.20). Capecitabine improved relapse-free survival (hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.99; P=0.04) and was associated with significantly fewer adverse events than fluorouracil plus leucovorin (P<0.001). Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.


  • Quality of Life in Women with Advanced Breast Cancer Treated with Docetaxel

    by Chris J. Twelves, David W. Miles, Angela Hall


  • A phase I trial of the DNA-hypomethylating agent 5-Aza-2'-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid tumours

    by C. Lee, K. Appleton, J. Plumb, S. Kaye, C. Cruickshank, C. Twelves, P. Vasey, I. Judson, R. Brown, H. Mackay

    2005 Background: There is increasing evidence that DNA hypermethylation of CpG islands at key genes is associated with chemo resistance. For instance, methylation of a CpG-island at the hMLH1 promoter may be a major mechanism for loss of MLH1 expression associated with chemo resistance. Decitabine (5-Aza-2'-deoxycytidine) is a demethylating agent which has been shown in in vivo studies to reactivate MLH1 expression leading to sensitisation of chemo resistant tumours to a range of cytotoxic drugs. This Phase I study investigated the feasibility of delivering a dose of decitabine which would cause demethylation and hence potential sensitisation without causing prohibitive myelosuppression in combination with carboplatin. Methods: Pts with a variety of malignancies were enrolled. The starting dose of decitabine (on Day 1) was 45mg/m2. This was escalated in steps of 45mg/m2. Carboplatin at a fixed dose of AUC5 was given on Day 8. The interval between decitabine and carboplatin was 8 days which was within the optimal time for demethylation from xenograft studies. Treatment was repeated every 4 weeks. Results: 14 heavily-pretreated pts have been enrolled to date (6M/8F). Median age: 55; mean PS (ECOG): 1. Pts have been treated at 3 dose levels of decitabine: 45, 90 and 135mg/m2. Median number of cycles: 2 (range 0.5–6). 13/14 patients were evaluable for toxicity. MTD was identified as decitabine 135mg/m2 with grade 4 febrile neutropenia (1 pt), and grade 4 neutropenia necessitating delay of cycle 2 for >7 days (1 pt). Other possible treatment-related toxicities included: nausea, vomiting, diarrhoea, fatigue, anorexia, anaemia (all ≤grade 2 and easily manageable). PD studies showed reduction in 5-methylcytosine to total cytosine ratios in DNA isolated from peripheral mononuclear cells at all dose levels, and was maximal between Days 8 and 12 following decitabine infusion Conclusion: This study confirms that the combination of decitabine and carboplatin is feasible. Futher patients are being accrued to assess PD effects in tumour as well as peripheral blood and buccal smears. No significant financial relationships to disclose.